University of California

Claude P Genain

Stephen L Hauser

Ilse Bartke

Jurgen Unger

Hans-Christian Von B&uuml;dingen

This invention pertains to the discovery that nerve growth factor (NGF) is capable of preventing further demyelination of nervous tissue in pathologies characterized by the demyelination of nervous tissue (e.g. multiple sclerosis). In one embodiment, this invention provides a method for inhibiting demyelination in a subject having an inflammatory disease of a nervous tissue. The method involves administering an effective amount of NGF, an NGF analogue, or an active fragment of NGF where the effective amount is sufficient to downregulate the production of interferon &#x3bb; by T cells infiltrating the central nervous system and/or to upregulate IL-10 production by glial cells.

NGF for the prevention of demyelination in the nervous system

The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.

Inhibiting MOG-antibody binding

The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences derived from combinatorial phage display libraries selected for high-affinity binding to myelin oligodendrocyte glycoprotein.

Growing community of inventors

Mill Valley, CA, United States of America

Claude P Genain